Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices (NCT01970748) | Clinical Trial Compass
UnknownPhase 4
Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
Taiwan200 participantsStarted 2009-08
Plain-language summary
Randomized comparison within the endoscopic esophageal varices ligation versus non-selective beta-blocker in the primary prevention of esophageal variceal bleeding in patients with HCC.
Who can participate
Age range20 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Between 20 and 80 years old
* Hepatocellular carcinoma (HCC) associated with esophageal varices
* F2 or F3 esophageal varices (Beppu et al classification)
* Hepatocellular carcinoma (HCC) associated with portal thrombosis
Exclusion Criteria:
* History of esophageal variceal bleeding
* Had received endoscopic variceal ligation (EVL) or endoscopic injection sclerotherapy (EIS)
* Pregnancy, or the patients with other terminal illness (such as other terminal cancers, heart failure, renal failure...)
* Propranolol contraindications (such as atrioventricular block, heart failure, chronic obstructive pulmonary disease, asthma, poorly controlled diabetes, severe peripheral arterial disease...)